Related Experiment Video
Updated: Jun 18, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for
Sung-Young Shin1,2, Nicole J Chew1,2, Milad Ghomlaghi1,2
1Cancer Program, Biomedicine Discovery Institute, Monash University, Melbourne, Australia.
Abstract:
Oncogenic FGFR4 signaling represents a potential therapeutic target in various cancer types, including triple-negative breast cancer and hepatocellular carcinoma. However, resistance to FGFR4 single-agent therapy remains a major challenge, emphasizing the need for effective combinatorial treatments. Our study sought to develop a comprehensive computational model of FGFR4 signaling and to provide network-level insights into resistance mechanisms driven by signaling dynamics. An integrated approach, combining computational network modeling with experimental validation, uncovered potent AKT reactivation following FGFR4 targeting in triple-negative breast cancer cells. Analyzing the effects of cotargeting specific network nodes by systematically simulating the model predicted synergy of cotargeting FGFR4 and AKT or specific ErbB kinases, which was subsequently confirmed through experimental validation; however, cotargeting FGFR4 and PI3K was not synergistic. Protein expression data from hundreds of cancer cell lines was incorporated to adapt the model to diverse cellular contexts. This revealed that although AKT rebound was common, it was not a general phenomenon. For example, ERK reactivation occurred in certain cell types, including an FGFR4-driven hepatocellular carcinoma cell line, in which there is a synergistic effect of cotargeting FGFR4 and MEK but not AKT. In summary, this study offers key insights into drug-induced network remodeling and the role of protein expression heterogeneity in targeted therapy responses. These findings underscore the utility of computational network modeling for designing cell type-selective combination therapies and enhancing precision cancer treatment. Significance: Computational predictive modeling of signaling networks can decipher mechanisms of cancer cell resistance to targeted therapies and enable identification of more effective cancer type-specific combination treatment strategies.
Insights
Targeting FGFR4 in cancer can lead to resistance. Computational modeling revealed that combining FGFR4 inhibitors with AKT or ErbB kinase inhibitors can overcome resistance in certain cancers, improving targeted therapy effectiveness.
Area of Science:
- Oncology
- Computational Biology
- Systems Biology
Background:
- Oncogenic FGFR4 signaling is a therapeutic target in cancers like triple-negative breast cancer and hepatocellular carcinoma.
- Resistance to single-agent FGFR4 therapy necessitates the development of effective combination treatments.
Purpose of the Study:
- To develop a computational model of FGFR4 signaling to understand resistance mechanisms.
- To identify synergistic combination therapies for FGFR4-targeted treatments.
Main Methods:
- Integrated computational network modeling and experimental validation.
- Systematic simulation of cotargeting specific network nodes.
- Incorporation of protein expression data from diverse cancer cell lines.
Main Results:
- AKT reactivation was observed upon FGFR4 targeting in triple-negative breast cancer cells.
- Synergy was predicted and validated for cotargeting FGFR4 with AKT or ErbB kinases, but not PI3K.
- ERK reactivation and synergy with MEK inhibition were observed in specific hepatocellular carcinoma cell lines.
Conclusions:
- Computational modeling provides insights into drug-induced network remodeling and resistance.
- Protein expression heterogeneity influences targeted therapy response.
- This approach enables the design of cell type-selective combination therapies for precision cancer treatment.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Intracellular Signaling Affects Focal Adhesions
Some...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Hedgehog Signaling Pathway
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...

